Fact CheckerSign in

NCT06316284Not yet recruiting

miRNA in Chronic Kidney Diseases

The Role of miRNAs in the Regulation of Oxidative Stress and Microvascular Reactivity in Chronic Kidney Disease

Source: ClinicalTrials.gov · Last updated 18 Mar 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
90 (estimated)
First submitted
2 Mar 2024
Start date
1 Apr 2024
Primary completion date
31 Dec 2025
Lead sponsor
Josip Juraj Strossmayer University of Osijek
NCT number
NCT06316284

What you commit to

  • Study type: Observational
  • Planned participants: 90
  • From 1 Apr 2024 to the primary completion date, 31 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • cardiovascular diseases, but hypertension
  • diabetes
  • cerebrovascular diseases
  • peripheral artery disease

Who the study is looking for

  • healthy normotensive adults (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \<140/90 mmHg)
  • hypertensive adults (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \>140/90 mmHg)
  • patients with chronic kidney disease stage 3-5 (eGFR CKD-EPI\< 60 mL/min/1.73 m2)

Age in the registry: 18 years to 69 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Faculty of Medicine Osijek
Coordinator of this site? Confirm its status
OsijekCroatiaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.